ENVERIC BIOSCIENCES, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
ENVERIC BIOSCIENCES, INC. (ENVB) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $1.98 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-04-01.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2021-04-01
- ENVERIC BIOSCIENCES, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2020 was $1.98M.
- ENVERIC BIOSCIENCES, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2016 was $1.46M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|
| 2020-12-31 | $1.98M 10-K · filed 2021-04-01 | |
| 2016-12-31 | $1.46M 10-K/A · filed 2017-04-04 | |
| 2015-12-31 | $141.91K 10-K/A · filed 2017-04-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |